Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Investigators will evaluate the safety and efficacy of combination neoadjuvant therapy using
intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with Muscle Invasive
Bladder Cancer (MIBC).
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute